Vinay Prasad: An evidence based embarrassment
Vibay Prasad, Professor in the Department of Epidemiology and Biostatistics at the University of California San Francisco, shared a post by Clay Reed, Hematologist and Oncologist at Mercy Coletta Cancer Center, on X, adding:
“Ha! Isa-KRD has more MRD negativity than KRD. Except KRD failed to beat VRD. And has more cardiotoxicity. And even VRD vs RD (rates of all post protocol care post RD never adequately reported).
Myeloma is a sea of studies without any standard of care. An evidence based embarrassment.”
Quoting Clay Reed‘s post:
“Myeloma trials be like:
Let’s see what happens to a surrogate marker that doesn’t matter with a non standard of care regimen versus a non standard of care regimen + new expensive drug.
Conclusion: easier way to sell more drug by confusing everyone.”
Source: Vinay Prasad/X and Clay Reed/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023